Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg in Asian adults with obesity
NCT04998136Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Novo Nordisk. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04998136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998136.